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Therapy for Lysosomal Storage Disorders: a Matter for Stem Cells
                                       Editorial
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*Department of  Chemistry, Biology and Biotechnology, University of  Perugia, Via del Giochetto, Italy.
The therapeutic potential of  stem cells is based on their own 
physiological activity on maintain the tissue homeostasis. Thank 
to the asymmetric division stem cells generate one stem cell that 
remain within the niche and one progenitor cell that entries to a 
differentiation program and in turn repopulate the tissue where 
they reside [1-2]. Noteworthy, stem cells preserve this regenera-
tive property even after their transplantation in a host damaged 
tissue because of  they recognize the host microenvironment and 
start to activate a tissue repairing program [1-4]. 
Thus, many diseases have been treated by stem cell replacement 
approaches with or without genetherapy combination in the cases 
of  genetic disorders [3-6]. Of  note, outcomes have been shown 
the potential of  stem cells to reestablish cells tissue of  different 
ontogenic origin indicating a cell reprogramming activity perhaps 
induced by the host tissue toward the implanted donor stem cells
[1]. Therefore, bone marrow transplantation (BMT) of  hemat-
opoietic stem cells (HSCs) has been successful applied for the 
treatment of  hematological diseases, but also for the therapy of  
nonhematopoietic diseases such as Lysosomal Storage Disorders 
(LSDs) [5,7-8]. 
LSDs are a group of  genetic diseases caused by deficiency of  re-
lated lysosomal enzymes or cofactors as consequence of  muta-
tion in a deputed gene [9-10]. Lysosomal enzymes are involved 
on the degradation of  the most biomacromolecules as well as on 
the production of  intermediate compounds crucial for several cell 
functions [5-6,8-9]. Absence of  such enzymes/cofactors produc-
es accumulation of  undegraded substrates and thereby cell dys-
functions and death of  patients at pediatric age in the most severe 
forms of  LSDs [5-6,8-9]. Therapy for LSDs generally consists 
on supportive care. Effort has been made by nonconventional 
approaches ranging from enzyme replacement therapy to stem 
cell replacement therapy with or without gene therapy combina-
tion [5,7]. Benefits emerge by a recent work by Naphade S. and 
coworkers, demonstrating the capability of  HSCs to restore the 
cystinosis, a multisystemic LSD, caused by a defective cystinosin 
(CTNS gene), a cystine lysosomal membrane transporter [11]. 
Successful outcomes are by stem cell treatment for the inherited 
Metachromatic Leukodystrophy (MLD), LSDs with neurological 
involvement caused by deficiency of  the enzyme arylsulfatase A 
(ARSA) [8]. In this clinical trial, after BMT of  adult HSCs engi-
neered with lentiviral vector expressing the ARSA gene, all three 
presymptomatic MLD patients showed widespread, robust and 
stable ARSA gene replacement and high enzyme expression in the 
hematopoietic lineages and in cerebrospinal fluid. Most important 
the treatment prevented the manifestation of  the disease and for 
the first time demonstrated that BMT of  engineered HSCs could 
be capable to cure neurodegenerative disorders [8]. For these re-
sults this approach is considered a breakthrough compared to 
previous conventional BMT treatments [12,13]. LSDs takes ad-
vantage also by the therapeutic potential of  other type of  stem 
cells. This is the case of  the Globoid cell leukodystrophy (GLD) 
a neurodegenerative LSDs caused by the deficiency of  galactocer-
ebrosidase (GALC) where adult bone marrow mesenchymal stem 
cells (BMSCs) transplantation into the animal model of  the dis-
ease, improved motor function, twitching symptoms, weight and 
decreased inflammatory cell, globoid cell, and apoptotic cell levels 
in the sciatic nerves compared to untreated mice [14]. Similarly, 
GLD takes benefit by intracerebral neonatal transplantation of  
neural stem cells (NSCs) that provides functional GALC enzyme 
and ameliorates the functional impairment in endogenous sub-
ventricular zone (SVZ) cells which seems to be involved on main-
taining a functional post-natal SVZ neurogenic niche [15]. 
Stem cells allow generating a disease model in vitro. In the case of  
LSDs, stem cell modeling led to elucidate pathophysiology mech-
anisms of  these diseases and in turn to develop more proficient 
therapeutic approaches. For instance, alteration of  self-renewal 
and proliferation of  NSCs and impairment of  neurons and oli-
godendrocytes survival is consequence of  absence of  GALC en-
zyme activity. Therefore insights into the mechanisms regulating 
the expression of  GALC in NSCs from GALC could improve 
the understanding of  GLD pathology [15]. Moreover, NSCs from 
the LSDs Tay-Sachs and Sandhoff  (GM2-gangliosidosis) animal 
models and their differentiated progenies recapitulated hexosa-
minidase activity, isoenzyme composition, gene expression and 
ganglioside metabolism observed during embryonic and postnatal 
brain development in GM2 gangliosidosis and allowed the eluci-
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dation of  the events linking the accumulation of  undegraded sub-
strates as cosenquence of  hexosaminidase activity deficiency [16].
In summary, the overall reports highlight the suitability of  stem 
cells for the treatment of  LSD but also for providing an in vitro 
model that, recapitulating the disease characteristics, allow the elu-
cidation of  the altered metabolic pathways. Thus, the therapy for 
LSD is a matter for stem cells.
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